Compare Quest Diagnostics Inc (DGX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Williams Companies Inc — how do they compare? Quest Diagnostics Inc trades at $204.98 (market cap $22.80B), while Williams Companies Inc trades at $75.34 (market cap $92.92B). The key difference: Williams Companies Inc is far larger — about 4.1× Quest Diagnostics Inc's market cap, and Williams Companies Inc pays the higher dividend (2.76%). Which is the better fit depends on your goals.
| DGX | WMB | |
|---|---|---|
Market Cap | $22.80B | $92.92B |
Sector | Health | Energy |
52-Week High | $216.02 | $79.40 |
52-Week Low | $166.42 | $56.51 |
Enterprise Value | $28.82B | $122.31B |
Dividend Yield | 1.67% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Williams Companies (WMB) trades at $74.46, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $11.95 billion in 2025 with a net income margin of 23.4%, and recent news highlights a $5.34 billion Blackstone-led investment to accelerate power projects. Valuation ratios include a P/E of 32.66 and P/B of 7.03, reflecting premium pricing relative to historical levels.
WMB presents a positive outlook with a consensus price target of $85.67, indicating 15% upside potential, supported by stable cash flows and strategic investments in energy infrastructure. Risks include exposure to natural gas price volatility and high debt levels, but the company's fee-based contracts and growth initiatives provide a buffer against market swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
